• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » BoSci acquires maker of world’s only lead-less ICD in a deal worth up to $1.35B

BoSci acquires maker of world’s only lead-less ICD in a deal worth up to $1.35B

March 9, 2012 By MassDevice staff

S-ICD

Boston Scientific (NYSE:BSX) exercised its option to acquire Cameron Health Inc., maker of the world’s only commercially available lead-less implantable cardioverter defibrillator which boasts the tag-line "Protection…without touching the heart."

Boston Scientific agreed to pay $150 million up-front, with another $150 million to be paid upon FDA approval for the device and up to $1.05 billion in potential payments on achievement of revenue-based milestones over a 6-year period, according to a press release.

The S-ICD system, unlike traditional ICDs, sits just beneath the skin and does not rely on wires relayed through blood vessels and connected to the heart in order to provide heart rhythm therapy.

The device is not yet available in the U.S., but Cameron Health filed for FDA pre-market approval in December 2011 and Boston Scientific anticipates regulatory approval in the first half of 2013, according to a press release.

Cameron Heath, who in September 2010 elected 33-year Medtronic veteran Warren Watson to chair of its board of directors, completed enrollment in May 2011 for a clinical study aimed at winning FDA approval.

The device has CE Mark approval in the European Union and has been on the market in several European countries since 2009. It has been implanted in about 1,000 patients worldwide, according to a press release.

"The S-ICD system represents a new category of rhythm management devices that is unlike anything available today," Dr. Kenneth Ellenbogen, professor of medicine and director of the electrophysiology lab at the Medical College of Virginia, said in prepared remarks.  "This system provides physicians with a new alternative in the treatment of patients at risk for sudden cardiac arrest and should become first-line therapy for patients who may benefit from not having a lead in the heart."

BoSci expects the acquisition to close in the 2nd or 3rd quarter of 2012, according to the release.

BSX jumped 3.5 percent on Wall Street today, trading at $5.93 around 5:45 p.m.

Filed Under: Mergers & Acquisitions, News Well Tagged With: Boston Scientific, Cameron Health Inc., Cardiac Rhythm Management

More recent news

  • GE HealthCare expands digital imaging portfolio with enhanced MIM Encore software
  • Accelus wins FDA clearance for MRI compatibility of FlareHawk spinal implants
  • Presidio wins FDA IDE for ultra-low frequency neuromod, hires new CFO
  • Epiminder study backs implantable EEG tech
  • Neurent Medical wins FDA nod for next-gen chronic rhinitis treatment

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy